| SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness KS Corbett, DK Edwards, SR Leist, OM Abiona, S Boyoglu-Barnum, ... Nature 586 (7830), 567-571, 2020 | 1526 | 2020 |
| Codon optimality is a major determinant of mRNA stability V Presnyak, N Alhusaini, YH Chen, S Martin, N Morris, N Kline, S Olson, ... Cell 160 (6), 1111-1124, 2015 | 1002 | 2015 |
| mRNA structure regulates protein expression through changes in functional half-life DM Mauger, BJ Cabral, V Presnyak, SV Su, DW Reid, B Goodman, K Link, ... Proceedings of the National Academy of Sciences 116 (48), 24075-24083, 2019 | 395 | 2019 |
| Human 5′ UTR design and variant effect prediction from a massively parallel translation assay PJ Sample, B Wang, DW Reid, V Presnyak, IJ McFadyen, DR Morris, ... Nature biotechnology 37 (7), 803-809, 2019 | 284 | 2019 |
| Systemic messenger RNA therapy as a treatment for methylmalonic acidemia D An, JL Schneller, A Frassetto, S Liang, X Zhu, JS Park, M Theisen, ... Cell reports 21 (12), 3548-3558, 2017 | 249 | 2017 |
| N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density YV Svitkin, YM Cheng, T Chakraborty, V Presnyak, M John, N Sonenberg Nucleic acids research 45 (10), 6023-6036, 2017 | 226 | 2017 |
| Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates X Zhu, L Yin, M Theisen, J Zhuo, S Siddiqui, B Levy, V Presnyak, ... The American Journal of Human Genetics 104 (4), 625-637, 2019 | 133 | 2019 |
| A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques P Zhang, E Narayanan, Q Liu, Y Tsybovsky, K Boswell, S Ding, Z Hu, ... Nature medicine 27 (12), 2234-2245, 2021 | 107 | 2021 |
| Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia L Jiang, JS Park, L Yin, R Laureano, E Jacquinet, J Yang, S Liang, ... Nature Communications 11 (1), 5339, 2020 | 97 | 2020 |
| TbRGG2, an essential RNA editing accessory factor in two Trypanosoma brucei life cycle stages JC Fisk, ML Ammerman, V Presnyak, LK Read Journal of Biological Chemistry 283 (34), 23016-23025, 2008 | 81 | 2008 |
| The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G JH Miller, V Presnyak, HC Smith Retrovirology 4, 1-11, 2007 | 76 | 2007 |
| The DHH1/RCKp54 family of helicases: an ancient family of proteins that promote translational silencing V Presnyak, J Coller Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1829 (8), 817-823, 2013 | 75 | 2013 |
| Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding RP Bennett, V Presnyak, JE Wedekind, HC Smith Journal of Biological Chemistry 283 (12), 7320-7327, 2008 | 75 | 2008 |
| A type III protein arginine methyltransferase from the protozoan parasite Trypanosoma brucei JC Fisk, J Sayegh, C Zurita-Lopez, S Menon, V Presnyak, SG Clarke, ... Journal of Biological Chemistry 284 (17), 11590-11600, 2009 | 66 | 2009 |
| TbRGG2 facilitates kinetoplastid RNA editing initiation and progression past intrinsic pause sites ML Ammerman, V Presnyak, JC Fisk, BM Foda Rna 16 (11), 2239-2251, 2010 | 64 | 2010 |
| Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease P Martini, SG Hoge, K Benenato, V Presnyak, I McFadyen, ... US Patent 10,519,455, 2019 | 58 | 2019 |
| Oligonucleotide sequence mapping of large therapeutic mRNAs via parallel ribonuclease digestions and LC-MS/MS T Jiang, N Yu, J Kim, JR Murgo, M Kissai, K Ravichandran, EJ Miracco, ... Analytical chemistry 91 (13), 8500-8506, 2019 | 54 | 2019 |
| mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease J Cao, M Choi, E Guadagnin, M Soty, M Silva, V Verzieux, E Weisser, ... Nature Communications 12 (1), 3090, 2021 | 51 | 2021 |
| MRNA combination therapy for the treatment of cancer JP Frederick, S Hewitt, A Bai, SG Hoge, V Presnyak, I McFadyen, ... US Patent 10,335,486, 2019 | 49 | 2019 |
| Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c. Abcb4-/-mouse model of PFIC3 G Wei, J Cao, P Huang, P An, D Badlani, KA Vaid, S Zhao, DQH Wang, ... Journal of hepatology 74 (6), 1416-1428, 2021 | 46 | 2021 |
